How Hollar was paid
$19M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Jason M. HollarChief Executive Officer | $1,492,329 | $13,431,441 | $3,551,742 | $500,683 | $18,976,195 |
| Aaron E. AltChief Financial Officer | $871,164 | $3,977,813 | $1,303,262 | $57,796 | $6,210,035 |
| Stephen M. MasonChief Executive Officer, Global Medical Products and Distribution Segment | $741,932 | $3,357,917 | $593,545 | $51,650 | $4,745,044 |
| Deborah L. WeitzmanChief Executive Officer, Pharmaceutical and Specialty Solutions Segment | $741,932 | $3,771,217 | $964,511 | $30,197 | $5,507,857 |
| Jessica L. MayerChief Legal and Compliance Officer | $716,932 | $3,202,943 | $975,027 | $30,450 | $4,925,352 |
What changed and why
- $19M$18,976,195: CEO total compensation decreased from $25,651,209 in fiscal 2024.
- $13.4M$13,431,441: CEO stock awards decreased from $20,640,912, which included incremental modification expense in fiscal 2024.
- 212%212%: Fiscal 2023–2025 PSUs settled at this payout level after financial over-performance.
- 20%20%: An upward TSR modifier was applied to the Fiscal 23–25 PSU payout.
- 70%70%: Fiscal 2025–2027 PSU payout weighting is based on adjusted diluted EPS CAGR and average annual dividend yield.
- $446K$445,557: Incremental cost of the CEO’s personal corporate-aircraft use was included in all other compensation.
Other Cardinal Health proxy statements
- 2026 proxy statement
Jason M. Hollar paid $22.6M (+19% on the year), pay ratio 288:1.
Filed Sep 21, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.